Fidaxomicin denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for fidaxomicin are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Limits Fidaxomicin Quantities — and Why You Can Appeal

Fidaxomicin is an oral antibiotic approved by the FDA specifically for Clostridioides difficile infection (CDI). UnitedHealthcare's quantity-limit restriction reflects a formulary management tool tied to the FDA-approved course duration: the plan's dispensing limit is set to align with the labeled treatment regimen. If your prescription as written exceeds that limit — or if a refill is requested — the claim will reject at the pharmacy.

This kind of denial is routine and highly appealable, because quantity-limit decisions are almost always resolved at the first internal appeal level when the prescriber documents medical necessity clearly.

## Your Federal Appeal Rights

• Internal appeal: Under ACA §2719 and ERISA §503, you have the right to a full-and-fair internal review. Submit within your plan's deadline (typically 180 days from the denial notice).
• External review: If the internal appeal fails, you may escalate to an independent external reviewer under the ACA external-review framework. Most plans allow approximately four months from the original denial to request external review.
• Expedited review: If your condition is urgent — for example, active CDI requiring prompt treatment — you can request an expedited internal and external review, with decisions typically required within 72 hours.

## What to Gather Before You Appeal

1. Diagnosis confirmation — chart notes or lab results confirming C. difficile infection, the episode count (primary vs. recurrence), and severity classification per your clinician's assessment. 2. Prior treatment history — dates, agents used, doses, outcomes, and any recurrence documentation for previous CDI episodes. 3. Prescriber medical-necessity letter — your physician should explain why the quantity prescribed is necessary, citing the FDA-approved prescribing label's recommended regimen and how your specific clinical situation requires the quantity requested. 4. Relevant guideline support — your prescriber can reference the applicable infectious disease society guideline (such as those from IDSA/SHEA) generically, without needing to reproduce numeric thresholds.

## Criteria-Mapping Structure

Build a one-page grid:

| Plan Requirement | Chart Evidence | |---|---| | Diagnosis of CDI confirmed | [Lab result date + result] | | Episode type (primary/recurrent) | [Chart note date] | | Quantity requested matches labeled regimen | [Prescribing label citation] | | No alternative agent clinically appropriate | [Prescriber attestation] |

Copy each requirement verbatim from UHC's published coverage policy and answer each row with the exact chart fact. Attach the FDA prescribing label page that specifies the approved regimen to show the quantity requested is consistent with the label — this directly rebuts the plan's justification for the limit.